



M&A in the CRO, CMO/CDMO business Q2 2018

Allyum's industry expert, Marc KOBYLINSKI, gives his Q2 2018 insights on the CRO, CMO & CMDO industry

"The 2nd quarter confirms the consolidation trends in the industry led by both Strategic and Financial players. As previously stated, CRO M&A activities faces a slowdown for this quarter: LabCop has acquired Sciformix for strengthening their position in the later phases development and Precision therapeutics enters into an agreement with Helomics for reinforcing their CRO capabilities. CMDO industry remains a hotspot for transactions. Key players look for grasping advanced and specialized technologies and manufacturing capabilities while others look for extending their offer on a global reach: Catalent acquired Juniper, Novacap enters into agreement with PCI and MDP, the US-based private equity firm has agreed to acquire a majority stake in Alcami. Even in Belgium, the M&A activities remain intense and not only in the Biotech industry (Ogeda acquired by Astellas, Tigenix by Takeda, Ablynx by Sanofi and UCB acquired Proximagen) but also recently in the CDMO sector: Ardena acquired Syntagon, Great Point Partners invested in Mastershell and Global Health Investment Fund, Korea Investment Partners, European Business and Innovation Center and Inventures SA in Univercells. The recent transactions prove that Belgium does not only have a good soccer team but also good companies in the healthcare industry."



- PROMINENT TRANSACTIONS -

Prominent transactions of the last 90 days



Precision Therapeutics Inc., a listed US-based company headquartered in Eagan, Minnesota, is engaged in applying artificial intelligence to personalized medicine and drug discovery, has agreed to acquire the remaining 75% stake in **Helomics Corporation**, the US-based company headquartered in Pittsburgh, Pennsylvania, is a precision diagnostic company and integrated clinical contract research organization.



Novacap SAS, a France-based manufacturer and distributor of chemical raw materials, has agreed to acquire **PCI Synthesis, Inc.**, the US-based pharmaceutical contract development and manufacturing organization (CDMO), for an undisclosed consideration.



Laboratory Corporation of America Holdings (LabCorp), the listed US-based clinical laboratory services company with clinical tests ranging from routine analyses to sophisticated molecular diagnostics, has acquired, **Sciformix Corporation**, the US-based company providing process, technology and consulting services to the life sciences industry, for an undisclosed consideration.



Madison Dearborn Partners, LLC (MDP), the US-based private equity firm, has agreed to acquire undisclosed majority stake in **Alcami Corporation**, the US based company providing pharmaceutical development and manufacturing services, from Ares Management LLC, the US-based private equity firm, and a subsidiary of Ares Capital Corporation, the listed US-based closed-ended fund management company, doing business primarily in private equity, for an undisclosed consideration.



Ardena, a Belgium-based contract development and manufacturing organization (CDMO), engaged in providing pharmaceutical development services and the development and manufacture of early phase clinical supplies and small-scale commercial batches, has acquired **Syntagon**, a leading Scandinavian-based contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.



Catalent, Inc., New Jersey-based listed company that provides development solutions and drug delivery technologies, has agreed to acquire **Juniper Pharmaceuticals, Inc.**, the listed Boston-based healthcare company which develops intra-vaginal therapeutics.



Growth
Equity Investment
→



Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, announced a growth equity investment in **MaSTherCell Global**, a Belgium-based global manufacturer of cell and gene therapies.



Growth
Equity Investment
→



Univercells, a Belgium-based technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions ranging from design and building of manufacturing facilities to maintenance and supply of bulk APIs and also focuses on developing vaccines, closed a €16 million series B backed by funds on three continents. financing round was led by the public health-focused **Global Health Investment Fund** (GHIF), which was structured by JPMorgan Chase and the Bill & Melinda Gates Foundation. **Korea Investment Partners** and two Belgian tech funds; **European Business and Innovation Center (EBIC)** and **Inventures SA**, along with several private investors, also contributed.

Source: MergerMarket

- ALLYUM'S INSIGHT -



Since 2004 Allyum has built up a substantial track record in steering corporate finance operations for mid-cap markets. Each member of our team has a professional background that reflects their attention to detail and comprehensive approach to their mission, as well as their passion for business development and financial operations.